Search of Biomarkers of Mineralocorticoid Receiver Activity : the Value of Neutrophil Gelatinase Associated Lipocalin (NGAL)in Serum or Urine in Human
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02129621|
Recruitment Status : Completed
First Posted : May 2, 2014
Last Update Posted : May 2, 2014
|Condition or disease||Intervention/treatment||Phase|
|Cardiovascular Diseases||Procedure: Urinary and blood lipococalin levels determination Drug: Spironolactone||Not Applicable|
This study is broken up into 5 groups:
The first is a pre-analytical study to determinate optimum conditions for lipocalin samples.
The second focuses on intra-individual variations of lipocalin levels in blood and urine.
The third determinate the normal values of lipocalin in blood and urine. Fourthly, we study the role of renal function on serum and urines lipocalin levels.
Fifthly, we study the role of anti-aldosterone treatment on patients who suffer of primary hyperaldosteronism.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||42 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prospective Study of Neutrophil Gelatinase Associated Lipocalin (NGAL)as a Biomarker of Mineralocorticoid Receiver Activity in Human: Proof of Concept.|
|Study Start Date :||May 2010|
|Actual Primary Completion Date :||November 2012|
|Actual Study Completion Date :||November 2012|
- Procedure: Urinary and blood lipococalin levels determination
Blood test on an empty stomach. Urinary taking on arrival in the service
- Drug: Spironolactone
For the group 5, at the time of the V0 visit, a treatment by aldactone will be set up (posology: 1 to 2 mg/kg).Other Name: ALDACTONE
- Lipocalin blood and urinary concentrations [ Time Frame: 8 months ]Serum and urinary lipocalin concentrations will be evaluated using comercially available kits (Kits lipocalin-2/NGAL (NCAL20))
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02129621
|Nancy, France, 54000|
|Georges Pompidou Hospital|
|Paris, France, 75015|
|Unit of arterial high blood pressure of the Georges Pompidou Hospital|
|Paris, France, 75015|
|Principal Investigator:||Michel AZIZI, Pr||Georges Pompidou Hospital, Paris|